Altimmune (ALT) Accumulated Expenses: 2010-2025
Historic Accumulated Expenses for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to $7.8 million.
- Altimmune's Accumulated Expenses rose 3.96% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 3.96%. This contributed to the annual value of $10.3 million for FY2024, which is 1.83% up from last year.
- Altimmune's Accumulated Expenses amounted to $7.8 million in Q3 2025, which was down 6.78% from $8.4 million recorded in Q2 2025.
- Over the past 5 years, Altimmune's Accumulated Expenses peaked at $19.1 million during Q3 2021, and registered a low of $7.4 million during Q2 2023.
- Over the past 3 years, Altimmune's median Accumulated Expenses value was $8.7 million (recorded in 2025), while the average stood at $9.0 million.
- In the last 5 years, Altimmune's Accumulated Expenses surged by 252.86% in 2021 and then tumbled by 38.39% in 2023.
- Quarterly analysis of 5 years shows Altimmune's Accumulated Expenses stood at $10.2 million in 2021, then increased by 20.67% to $12.2 million in 2022, then dropped by 17.77% to $10.1 million in 2023, then climbed by 1.83% to $10.3 million in 2024, then grew by 3.96% to $7.8 million in 2025.
- Its last three reported values are $7.8 million in Q3 2025, $8.4 million for Q2 2025, and $8.7 million during Q1 2025.